Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Bass

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Clinical Pharmacology and Therapeutics|September 1, 2020
Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry PerspectiveHugo M Vargas, Michael G Rolf, Todd A Wisialowski, et al.
Journal of Medicinal Chemistry|March 3, 2022
Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral DosingDerun Li, David L Sloman, Abdelghani Achab, et al.
Journal of Medicinal Chemistry|May 27, 2026
Discovery Process of Enlicitide, a Highly Engineered Macrocyclic Peptide Therapeutic, through Issue-Driven Fragment-Based Synthetic Assembly and SARHubert Josien, Anilkumar G Nair, Fa-Xiang Ding, et al.
Journal of Medicinal Chemistry|April 29, 2026
Discovery of Potent and Selective Benzothiophene Difluoromethyl Phosphonate (DFMP) PTPN2/N1-Dual InhibitorsXiao Mei Zheng, David A Candito, James Jewell, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Clinical Pharmacology and Therapeutics|September 1, 2020
Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry PerspectiveHugo M Vargas, Michael G Rolf, Todd A Wisialowski, et al.
Journal of Medicinal Chemistry|March 3, 2022
Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral DosingDerun Li, David L Sloman, Abdelghani Achab, et al.
Journal of Medicinal Chemistry|May 27, 2026
Discovery Process of Enlicitide, a Highly Engineered Macrocyclic Peptide Therapeutic, through Issue-Driven Fragment-Based Synthetic Assembly and SARHubert Josien, Anilkumar G Nair, Fa-Xiang Ding, et al.
Journal of Medicinal Chemistry|April 29, 2026
Discovery of Potent and Selective Benzothiophene Difluoromethyl Phosphonate (DFMP) PTPN2/N1-Dual InhibitorsXiao Mei Zheng, David A Candito, James Jewell, et al.
Pageof 7